

# Monitoring Adverse Reactions to TB Medications

Melissa Davis, RN January 25, 2024

Introduction to TB Nurse Case Management Online January 8, 2024 – February 9, 2024 San Antonio, Texas / Online Course

# Melissa Davis, RN has the following disclosures to make:



 No relevant financial relationships with any commercial companies pertaining to this educational activity



Texas Department of State Health Services

# Monitoring for Adverse Reactions to TB Medications

Melissa Davis, RN

TB Program Manager,

Texas Department of State Health Services, Region 11

Special Thanks to Mathew Whitson, RN, Communicable Disease Consultant, Region 8






Texas Department of State Health Services

- Describe the monitoring process for adverse drug events associated with anti-TB drugs.
- Examine the difference between side effects and drug toxicities.
- List the most common adverse effects of TB therapy.




- Obtain patient information
  - Patient's weight
  - Patient's medications
  - Patient's past medical history
- Establish a rapport with the patient
  - Determine what barriers you may encounter
- Draw baseline labs
  - CBC, CMP (with creatinine level), Glucose, HIV test





- Provide education to the patient and additional family members as needed.
  - Treatment will be for months, not days.
  - Provide educational materials on medications and side effects.
  - What are the expectations of the patient? The nurse?
- Provide notification to the patient's physicians.
  - Critical if medications interact with each other.





- Medication classes that can decrease in efficacy
  - Beta blockers
  - Anticoagulants
  - Anti-depressants
  - Anti-diabetic drugs
  - Anti-anxiety agents
  - Anti-psychotics
  - ACE inhibitors
  - HMC CoA Inhibitors (statins)
  - Hormonal Contraceptives
  - Immunosuppressants
  - Opiates
- May need dosage adjustment.





- Perform baseline toxicity screening.
  - Are signs and symptoms of toxicity present before medications administered?
  - Vision screening
    - Red/green color discrimination
    - Visual acuity
  - Hearing screening (if needed)
- Ensure that the medication orders are correct.





#### 

- Medical History
- MD/RN evaluation
- Chest X-ray
- Sputum Specimen
- HIV Testing
- Toxicity assessment
  - Vision screenings
  - Hearing screenings
- Weight
- Labs (CBC, CMP, etc.)

Texas Department of State Health Services Clinical Assessment for Tuberculosis Medication Toxicity											
	C	linical Assessme	ent for 1					•			
NAME:				D.O.B.	:	/	/	SS#:	/	/_	
Adverse Drug React	ion Assessment: Ask	all the below questions	to monitor	for medica	tion toxicit	y, noting th	at some syr	mptoms may	y be more o	commonly a	ssociated
		associated with second-									
other regimens. Docu	ment <u>any</u> [+], incl. pot	ential pregnancy in wo							_	_	
			Date	Date	Date	Date	Date	Date	Date	Date	Date
Weight											
Temperature											
Blood Pressure											
Pulse	f 4b . f . 11				-E-i-		12				
Abdominal pain		symptoms now o	r sunce y	our iast	сишс ар	pomitme	ut:				
Abnormal behavi											
Allergic reaction											
Bruises, red/purp											
Change in heart											
Change in urine											
Convulsions**	output						_				
	e colored) or char	nge in color!									
	ness/hearing loss*										
	n (redness, excess										
Fever or chills†	a (remain), escess						-				
Flu-like sympton	ns†										
Headaches (chro											
Increased gas/sto	mach cramps**										
Jaundice (yellow											
	ng (chronic) - PZA	4									
Light colored sto	ols†										
Loss of appetite <sup>†</sup>											
Malaise/fatigue											
Memory Loss**											
	Mood changes/depression**										
Musculoskeletal											
Nausea/vomiting											
	ng/pain, arms, legs										
	diness/Restlessne	SS									
Skin discoloratio											
Skin rashes/itchin											
Sleep problems*											
Sores on lips or i											
	Shortness of breath										
	Teeter/Fall to Left or Right when standing (eyes closed) Unusual bleeding (nose, gums, stool, urine, etc.) or									-	-
easy bruising - F											
Vertigo/dizzines			$\vdash$	$\vdash$	<del></del>	<del>                                     </del>	<del>                                     </del>		<del>                                     </del>	<del>                                     </del>	<del>                                     </del>
	changes in vision'	*** EMB DDT		_			_				
Weakness, tiredn		- EMD, RDI		<del>                                     </del>							
Weave/Stagger when walking (normal gait) Use of over the counter drugs, ie. Tylenol products?											
	it signs of pregna					_					
Drug Issued		Route/ Frequency	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount
Diag Linea	mag zoon zap	and a requesty									
				_							
N. 6710											
Name/Title				<del></del>			<del></del>				
Interpreter				_							
Next Appt.		<u>.</u>	Ļ	L	L.,		Ļ				



**Health Services** 

## **Baseline: Prior to Starting Anti-TB meds**

Texas Department of State Health Services Vision/Hearing Screening Form																			
						VIS	1011/1		_		_								
NAME	3:							D	.O.B.	-	/_			_ 5	S#:_		_	_/_	
Red/Green Color Discrimination:																			
evaluation	sark indicates if $\leq 7$ plates $\{N\} = Norn$	are read	as non	nal.		nall 14	plates.	Client n	anst bess	10 of	the first	11 plat	es for th	e test to	be regar	ded as n	ormal. l	Refer f	ie .
Ishihara		Red/G			_			Date	Date	Da	te	Date	Dat	, D	ate	Date	Dat		Date
Plate#	Reading	Deficie	BCY															_	
1	12	12					_		$\vdash$	+			+	$\rightarrow$			+	$\dashv$	
2	8	3					_		₩	_			—	$\rightarrow$			—	_	
3	29	2 70					$\dashv$		+	+			+	+		<u> </u>	+	$\dashv$	
5	74	70 21					$\dashv$		-	+	_	-	+	+		<del>                                     </del>	+	$\dashv$	
6	7	21 X					$\dashv$		+	+			+	+		$\vdash$	+	$\dashv$	
7	45	X					$\dashv$		+	+	_		+	+		$\vdash$	+	$\dashv$	
8	2	X					$\dashv$		+	+	-	_	+	$\rightarrow$		$\vdash$	+	$\dashv$	
9	X	2					$\dashv$		+	+	-		+	$\rightarrow$		$\vdash$	+	$\dashv$	
10	16	X					$\dashv$		+	+			+	+		$\vdash$	+	$\dashv$	
11	Traceable	v v				$\dashv$		_	+	-		+	$\rightarrow$		$\vdash$	+	$\dashv$		
	Protan Doutan						_												
		Strong	Mile		trong	Mild													
12	35	5	(3)			3 (5)	_		_	_			_	$\rightarrow$			_	_	
13	96	6	(9)			9 (6)	$\Box$		₩	—			—	$\rightarrow$		_	—	$\rightarrow$	
4	Can trace 2 lines	Purple	Purp (Rec		ted	Red (Purpl												- 1	
Results	e mas		(PARK	4		() tage			-	+			+	$\neg$		$\vdash$	+	$\neg$	
nitials			+	$\neg$		-	$\neg$		-	$\top$			+	$\neg$			+	$\neg$	
Visual Acuty:  If initial screen was conducted with corrective lenses (glasses or contacts), follow-up acroems must be done the same. A change of 1 or more lines from the initial across in either one or both eyes must be reported to the physician immediately.  Results: [P] = Pas [P] = Results: [P] = Resul																			
Distance Acuity			D	ate	Ds	te	Ds	ite	Date		Date		Date	D	ate	Dя	te	Da	te
Right Eve			2	0/	20.	,	20	/	20/		20/	$\neg$	20/	2	0/	20/		20/	
eft Eye				0/	20.		20		20/		20/		20/		0/	20/		20/	
Both Eye	5		2	0/	20.	1	20	/	20/		20/		20/	2	0/	20/		20/	
Results			$\Box$		$\perp$		$\perp$									$\perp$		$\perp$	
luitials					$\perp$		$\perp$									$\perp$		$\perp$	
Hearing Sweep Check:  When patient is taking emilacin, capreomycin, karamycin, or streptomycin, for each of the four frequencies listed, record the lowest level in decibels (dB) at which the person response. Record the findings for both the right and left our. Refer to an appropriately licensed professional if any two of the four frequencies are recorded as greater than 2.5 dB in either ear or the same car or if there is a change of decreased hearing level from baseline. Start with 40 dB, if heard decrease by 10 dB total in response is obtained and recorded. If a response is not heard at 40 dB, record as 40+dB.  Results: [1] = Pass [ n] = Refer [ 0] = Observe Ear [ n] = Right [ L] = Left																			
Frequenc	у	Date		Date		Date		Date		Date		Date		Date		Date		Date	
Ear		R	L	R	L	R	L	R	L	R	L	R	L	R	L	R	L	R	L
500 Hz																			
1000 Hz				-	-			+			-	+	$\top$	T	-			T	+
2000 Hz								$\top$				T	$\top$						$\top$
		_	-	_	_		-	_			_	$\overline{}$	$\overline{}$	$\overline{}$	-	_	_	-	$\overline{}$

\*\*\* From previous page: Changes in Vision may include blind spots in field of vision, blurred vision, changes in peripheral vision

TB205- Clinical Assessment for TB Medication Toxicity - Revised 8/2017

Texas Department of State Health Services Tuberculosis Case and Suspect Management Plan													
Patient's Name:		Initial Report Date & Source:											
Nurse Case Manager: Case Management Team:													
Directions: Blank boxes indicate week(s) TB service is to be provided. Document date and initials of the provider in the appropriate box when the task is completed. Document comments in progress notes.													
	Action Interval:	0 Begin	2 Wks	4 Wks	8 Wks	12 Wks	16 Wks	20 Wks	24 Wks	26 Wks			
	Date:												
Consents	General Consents, L-30, L-36, HIPAA, TB-209, interpreter form PRN; TB 409, TB 410, TB 411, etc.												
Responsibility	Assign nurse case manager; establish team; document in client's record												
	Obtain medical history; document on TB-202												
	Obtain release (L-30); request previous medical records												
	MD evaluation/review, document in progress notes												
	RN evaluation												
	IGRA or Mantoux skin test recorded in mm (if not												
Medical Evaluation	previously done) Chest X-ray (PA & Lateral if less than 18 years)												
Evaluation	Supervised sputum for AFB smear/culture according to				/ maren								
	protocol				tibility								
	HIV testing, unless patient has knowledge of HIV+												
	status or has documented negative HIV test result within 14 days of TB diagnosis												
	Labs per protocol or specific order												
	Nutritional assessment												
	Drug regimen according to protocol or specific order												
	Initiate DOT on all cases/suspects: Recommended Daily												
	X 8 weeks, then daily or 3X/week (Mon/Wed/Fri) until completion of adequate therapy; document DOT on TB-												
	206; other DOT dosing schedules may be ordered.												
Treatment	Pyrazinamide X2 months and ethambutol X2 months (or until susceptibilities are reported and client's												
Treatment	organism is known to be pan sensitive)												
	Vitamin B6 (if pregnant, diabetic, at risk for peripheral												
	neuropathy) Obtain Informed Consent form TB-411 (TB-411A, if												
	Spanish speaking, only) initially and for any drugs												
	added to regimen.												
Consultation	Obtain expert consult for drug resistant cases, complicated adult/pediatric cases or client who remains												
Consultation	symptomatic or sputum positive after 2 months' therapy;												
	written consult in client record												
	Clinical assessment according to protocol; document (TB-205 and progress note as appropriate)												

TB 201- Case Management Plan for Outpatient Care - Revised 08/2017

document (TB-205)

Rifabutin; document (TB-205)

Visual acuity (Sloan or Snellen) and color discriminatio (Ishihara Plates) initially and monthly if on EMB or

Hearing sweep check initially and monthly if on amikacin, capreomycin, kanamycin or streptomycin;

Toxicity/

Clinical

Assessment

# Administering the medications




Texas Department of State Health Services

 Ensure that the patient answers each question about toxicity before medications are given.

 Ensure that the correct dosage is given at each patient encounter.

 Ask open-ended questions in addition to the closed ended questions.



## Patient monitoring



Texas Department of State Health Services

- The frequency with which you monitor the patient depends on how the patient is responding to treatment.
  - How is the patient doing clinically?
  - Are there new s/sx of toxicity?
  - How were the baseline labs?
  - What do your standing delegation orders allow you to do?
- Patient should have a toxicity screening form completed at least monthly.



### Drug side effects



- Unpleasant, but usually mild
- Generally resolve during or after treatment.
- Do not usually require changes in therapy.
- Can include:
  - Gas or bloating
  - Mild nausea
  - Discoloration of body fluids (RIF)
  - Photosensitivity (RIF)
  - Rash (minor)
  - Fatigue



### Drug adverse effects



- Change in vision
- Hepatotoxicity
- Significant GI problems (severe vomiting)
- CNS toxicity
- Neurotoxicity
- Ototoxicity
- Renal toxicity
- Bleeding problems
- Rash (severe, systemic involvement)



# Adverse Drug Reactions



- More serious than side effects.
- May be life threatening
- Require modification of dose/discontinuation medications.
- Must be reported to the treating physician immediately.





#### 1st line TB medications

- Isoniazid
  - Kills rapidly dividing TB cells.
- Rifampin
  - Kills rapidly dividing TB cells.
  - Has some effect on semi-dormant TB cells.
- Pyrazinamide
  - Kills semi-dormant TB cells.
- Ethambutol
  - Protects against developing rifampin resistance.

2/14/2024 16




#### 1std line TB medications

- Isoniazid
  - Kills rapidly dividing TB cells.
- Rifampin
  - Kills rapidly dividing TB cells.
  - Has some effect on semi-dormant TB cells.
- Pyrazinamide
  - Kills semi-dormant TB cells.
- Ethambutol
  - Protects against developing rifampin resistance.

2/14/2024 17




- Isoniazid
  - Increases liver functions
    - Watch LFTs at baseline and throughout treatment.
    - Fatigue, jaundice, abdominal pain, dark urin light stools, nausea, poor appetite
  - Can cause peripheral neuropathy
    - Numbness/tingling to hands and feet.
  - Rash





- Rifampin
  - Increases liver functions
    - Watch LFTs at baseline and throughout treatment.
  - Can cause low platelet count.
    - Need baseline PLTs and monitoring for thrombocytopenia.
  - Orange discoloration of body fluids.
  - Can damage kidneys and cause decreased urine output.
  - Interacts with many other medications.
    - Get patient's medication list and review with your physician.





- Pyrazinamide
  - Increases liver functions
    - Watch LFTs at baseline and throughout treatment.
    - Watch Uric Acid level and monitor for joint pain.
    - Fatigue, jaundice, abdominal pain, dark urine, light stools, nausea, poor appetite
  - Can cause GI problems (upset stomach, lack of appetite)
  - Can cause rash.





Texas Department of State Health Services

- Ethambutol
  - Can cause eye damage
    - Blurred vision
    - Change in color vision
  - Monitor kidney functions to adjust dosage.
  - Can cause rash





## Fluroquinolones

Drug	Standard adult Dosing	Considerations	Side Effects				
Moxifloxacin	40mg once daily, PO or IV	Good CNS Penetration	GI upset, dizziness, hypersensitivity,				
Levofloxacin	750-1,000 mg once daily, PO or IV	Good CNS penetration; adjust dose with creatine clearance < 30; avoid caffeine, milk- based products, antacids, or mineral supplements within 2 hrs. of medication	photosensitivity, headaches, arthralgias, tendonitis, tendon rupture (rare), CNS irritability, QTc prolongation, thrush, peripheral neuropathy, elevated liver enzymes (rare hepatotoxicity with moxifloxacin)				



Texas Department of State Health Services


## **Vision Screening**


Ishihara Testing
Snellen Eye Exam





#### **Ishihara Test**


- Designed to give quick & accurate assessment of color vision
- Most effectively done in room with adequate daylight
- Held 75 cm from the patient (approx. arm length)
- Sit & tilt plate at right angle to patient's line of vision
- Screen all plates
















Normal (S,M,L)



Deutan or Red/Green (S,L)



Protan or Red/Green (S,M)



Tritan or Blue/Yellow (M,L)



#### **Visual Acuity**

- Place Snellen Chart on wall & have patient 20 feet from chart
- Have patient cover one eye at a time to read chart, recording the visual acuity for each eye, then with both eyes uncovered
- If patient misses only one letter have them continue reading the next line
- Record the last line the patient reads accurately
- If initial screen was conducted with corrective lenses(glasses/contacts), follow-up screens must be done the same.
- Change of 1 or more lines from initial screen in either one or both eyes must be reported to physician immediately





## Managing & Monitoring Visual Toxicities

- 1. Baseline & monthly visual acuity test (Snellen chart)
- 2. Baseline & monthly color discrimination test (Ishihara tests)
- 3. If change from baseline:
  - a. Hold Rx
  - b. Refer for Ophthalmologic evaluation
  - c. Permanent vision impairment if ethambutol continued

## Toxicity

Stop Medication ASAP with suspicion of vision, hearing loss, hepatitis, severe rash

In most cases vision or hearing loss is irreversible

Stopping medication halts extensiveness of damage

Better to miss a few doses vs disability



### Rashes/Itching



- All TB drugs can cause a rash
- If the rash is not severe, the patient may be able be treated with antihistamines or low dose prednisone.
- Assess the rash
  - Location
  - Does it itch?
  - When did it start?
  - What does it look like?
  - Has the patient tried any new products food, perfume, laundry detergent.
  - Have you ruled out other involvement?





#### Conclusion

- 1. Initial and ongoing assessment for medication side effects or adverse effects is crucial in maintaining a safe course of treatment for the patient.
- 2. Work with the patient and your treating physician to determine cause of side effects and how to address them.
- 3. You are the eyes and ears of the physician and the mouthpiece of the patient.



Texas Department of State
Health Services





Texas Department of State Health Services

- Heartland National TB Center website
  - http://www.heartlandntbc.org/products/ print out educational items)
- CDC TB website
  - https://www.cdc.gov/tb/default.htm
- Treatment guidelines
  - https://www.cdc.gov/tb/publications/guidelines/pdf/clin-infect-dis.-2016-nahid-cid\_ciw376.pdf
- TB education resources
  - https://findtbresources.cdc.gov/



Texas Department of State Health Services

# Thank you